Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashwani Kumar Arora

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Nursing New Zealand (Wellington, N.Z. : 1995)|June 26, 2009
Fairness in English language testingAshwani Kumar Arora
Human Vaccines & Immunotherapeutics|November 27, 2014
A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccinationKeith S Reisinger, Sandra J Holmes, Paola Pedotti, et al.
Infection & Chemotherapy|January 3, 2019
Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 YearsByung Wook Yoo, Chang Oh Kim, Allen Izu, et al.
Respiratory Research|February 25, 2021
Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepointsLucio Malvisi, Laura Taddei, Aparna Yarraguntla, et al.
Vaccine|July 31, 2014
Immunogenicity and safety of a single dose of a CRM-conjugated meningococcal ACWY vaccine in children and adolescents aged 2-18 years in Taiwan: results of an open label studyLi-Min Huang, Nan-Chang Chiu, Shu-Jen Yeh, et al.
Human Vaccines & Immunotherapeutics|April 14, 2017
Comparison of the immunogenicity and safety of the purified chick embryo cell rabies vaccine manufactured in India and Germany: A randomized, single blind, multicentre, phase IV clinical studyGadey Sampath, Angelika Banzhoff, Alaka Deshpande, et al.
Human Vaccines & Immunotherapeutics|January 17, 2018
Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized studyNan-Chang Chiu, Li-Min Huang, Arnold Willemsen, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in RussiaNatalia Ilyina, Susanna Kharit, Leila Namazova-Baranova, et al.
Respiratory Research|May 5, 2022
Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind studyIlaria Galgani, Margherita Annaratone, Daniela Casula, et al.
Journal of Travel Medicine|December 9, 2014
Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adultsMartin Alberer, Gerd Burchard, Tomas Jelinek, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Nursing New Zealand (Wellington, N.Z. : 1995)|June 26, 2009
Fairness in English language testingAshwani Kumar Arora
Human Vaccines & Immunotherapeutics|November 27, 2014
A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccinationKeith S Reisinger, Sandra J Holmes, Paola Pedotti, et al.
Infection & Chemotherapy|January 3, 2019
Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 YearsByung Wook Yoo, Chang Oh Kim, Allen Izu, et al.
Respiratory Research|February 25, 2021
Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepointsLucio Malvisi, Laura Taddei, Aparna Yarraguntla, et al.
Vaccine|July 31, 2014
Immunogenicity and safety of a single dose of a CRM-conjugated meningococcal ACWY vaccine in children and adolescents aged 2-18 years in Taiwan: results of an open label studyLi-Min Huang, Nan-Chang Chiu, Shu-Jen Yeh, et al.
Human Vaccines & Immunotherapeutics|April 14, 2017
Comparison of the immunogenicity and safety of the purified chick embryo cell rabies vaccine manufactured in India and Germany: A randomized, single blind, multicentre, phase IV clinical studyGadey Sampath, Angelika Banzhoff, Alaka Deshpande, et al.
Human Vaccines & Immunotherapeutics|January 17, 2018
Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized studyNan-Chang Chiu, Li-Min Huang, Arnold Willemsen, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in RussiaNatalia Ilyina, Susanna Kharit, Leila Namazova-Baranova, et al.
Respiratory Research|May 5, 2022
Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind studyIlaria Galgani, Margherita Annaratone, Daniela Casula, et al.
Journal of Travel Medicine|December 9, 2014
Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adultsMartin Alberer, Gerd Burchard, Tomas Jelinek, et al.
Pageof 3